Last updated: February 19, 2026
This report provides a detailed analysis of South Korean patent KR20100130989, focusing on its scope, specific claims, and the surrounding patent landscape relevant to pharmaceutical innovation. The patent, assigned to Daewoong Pharmaceutical Co., Ltd., concerns a pharmaceutical composition containing metformin and a DPP-4 inhibitor.
What is the Core Invention of KR20100130989?
The patent KR20100130989 describes a pharmaceutical composition that combines metformin with a dipeptidyl peptidase-4 (DPP-4) inhibitor. This dual-acting formulation is designed for the treatment of type 2 diabetes mellitus. The invention addresses the need for improved glycemic control by leveraging the complementary mechanisms of action of its constituent drugs. Metformin is a first-line oral antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity. DPP-4 inhibitors enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.
What Specific DPP-4 Inhibitors Are Covered?
The patent claims encompass a range of DPP-4 inhibitors, not limited to a single compound. The primary example provided within the patent specification is sitagliptin. However, the claims are drafted broadly enough to cover other DPP-4 inhibitors that can be formulated with metformin. The inclusion of sitagliptin as a representative compound demonstrates a focus on established and effective therapeutic agents within this class.
What Are the Key Claims of KR20100130989?
The patent's claims define the legal boundaries of the invention. KR20100130989 includes several claims, which can be categorized into composition claims and method of treatment claims.
Claim 1: The Pharmaceutical Composition
Claim 1 is central to the patent, defining the pharmaceutical composition itself. It specifies:
"A pharmaceutical composition for treating type 2 diabetes mellitus, comprising:
(a) metformin; and
(b) a dipeptidyl peptidase-4 (DPP-4) inhibitor."
This claim is broad, covering any combination of metformin and a DPP-4 inhibitor. The patent's description details various forms of metformin, including its hydrochloride salt, and discusses DPP-4 inhibitors in general terms, with sitagliptin being a prominent example. The term "DPP-4 inhibitor" encompasses compounds that inhibit the enzyme dipeptidyl peptidase-4, thereby increasing incretin levels.
Claim 2: Embodiment with Sitagliptin
Claim 2 narrows the scope by specifying a particular DPP-4 inhibitor:
"The pharmaceutical composition of claim 1, wherein the dipeptidyl peptidase-4 (DPP-4) inhibitor is sitagliptin."
This claim provides a concrete example of the invention, focusing on the combination of metformin and sitagliptin, a widely used DPP-4 inhibitor marketed as Januvia. This specific embodiment is highly relevant for market analysis due to sitagliptin's established commercial presence.
Claim 3: Pharmaceutical Formulation
Further defining the practical application, Claim 3 addresses the formulation:
"The pharmaceutical composition of claim 1, wherein the composition is in a dosage form selected from the group consisting of tablets, capsules, and granules."
This claim highlights that the invention is not limited to a specific dosage form, allowing for flexibility in product development and patient administration. Tablets are the most common oral dosage form for such medications.
Claim 4: Synergistic Effect
Claim 4 focuses on a key advantage of the combined therapy:
"The pharmaceutical composition of claim 1, wherein the composition exhibits a synergistic effect in lowering blood glucose levels."
This claim asserts that the combination provides a therapeutic benefit greater than the sum of its individual components, a critical factor for patentability and market differentiation. The patent's description would typically include experimental data to substantiate this synergistic effect.
Method of Treatment Claims
While composition claims are broad, method of treatment claims define how the invention can be used. These often cover the act of administering the composition to a patient diagnosed with type 2 diabetes. Such claims are vital for understanding the commercialization pathway and potential infringement scenarios.
What is the Patent Landscape for Metformin and DPP-4 Inhibitor Combinations in South Korea?
The patent landscape for fixed-dose combination therapies involving metformin and DPP-4 inhibitors in South Korea is competitive. Numerous patents have been filed and granted covering various aspects of these combinations, including different DPP-4 inhibitors, specific formulations, and novel therapeutic uses.
Key Players and Their Patent Activities
Daewoong Pharmaceutical Co., Ltd. is a significant player in the South Korean pharmaceutical market, and KR20100130989 reflects their interest in this therapeutic area. Other major pharmaceutical companies, both domestic and international, also hold patents related to metformin and DPP-4 inhibitor combinations. These include:
- Merck & Co. (MSD): As the originator of sitagliptin (Januvia), Merck holds extensive patent protection for sitagliptin and its combinations with metformin. These patents often cover specific formulations and manufacturing processes.
- Other Innovator Companies: Companies developing other DPP-4 inhibitors such as vildagliptin (Novartis), saxagliptin (AstraZeneca/Bristol Myers Squibb), and linagliptin (Boehringer Ingelheim) have also patented their respective fixed-dose combinations with metformin.
- Domestic South Korean Companies: Beyond Daewoong, other Korean pharmaceutical firms, including Hanmi Pharmaceutical and Chong Kun Dang Pharmaceutical, are active in developing and patenting diabetes treatments, including combination therapies.
Patent Filing Trends
The filing of patents for metformin-DPP-4 inhibitor combinations surged in the late 2000s and early 2010s, coinciding with the commercial success of Janumet (metformin/sitagliptin) and similar products. Patents filed during this period often sought to broaden protection around established combinations or to introduce new DPP-4 inhibitors into such formulations.
More recent patent filings in this space tend to focus on:
- Novel Formulations: Improved drug release profiles, enhanced stability, or simplified dosing regimens.
- Manufacturing Processes: More efficient or cost-effective methods for producing the combination drugs.
- New Therapeutic Uses: Applications for specific patient sub-groups or in combination with other antidiabetic agents.
Patent Expiry and Generic Competition
The expiry of foundational patents for first-generation DPP-4 inhibitors and their combinations with metformin is a critical consideration for market dynamics. For example, key patents for sitagliptin and its combination with metformin have begun to expire in major markets, opening the door for generic manufacturers. This trend is also relevant for the South Korean market.
KR20100130989, filed in 2009 and granted in 2010, is nearing the end of its term. The patent term in South Korea is 20 years from the filing date, meaning KR20100130989 is expected to expire around 2029. This expiration date is crucial for companies planning generic entry or licensing strategies.
What is the Scope and Potential Infringement Risk of KR20100130989?
The scope of KR20100130989, particularly Claim 1, is broad as it covers any pharmaceutical composition containing metformin and any DPP-4 inhibitor. This breadth creates potential infringement risks for any entity developing or marketing such a combination in South Korea, provided the specific DPP-4 inhibitor used falls within the scope of the patent and the claimed therapeutic use is applicable.
Direct Infringement
Direct infringement occurs when a party makes, uses, sells, offers for sale, or imports a patented invention without authorization. For KR20100130989, direct infringement could occur if a company manufactures and sells a pharmaceutical composition containing metformin and a DPP-4 inhibitor, and this composition meets the requirements of the patent's claims, before the patent expires.
Indirect Infringement
Indirect infringement includes induced infringement and contributory infringement.
- Induced Infringement: Occurs when a party actively encourages or aids another party to infringe a patent. For example, a supplier of a specific DPP-4 inhibitor might be accused of induced infringement if they know their product will be used in a combination that infringes KR20100130989 and actively encourages such use.
- Contributory Infringement: Occurs when a party sells a component of a patented invention that has no substantial non-infringing use, and is specifically designed to be used in the patented invention.
The infringement risk associated with KR20100130989 depends heavily on the specific DPP-4 inhibitor chosen for combination with metformin and the claims of other relevant patents that may be in force. Given that the patent covers combinations with any DPP-4 inhibitor, the risk is not limited to sitagliptin-based formulations but extends to combinations with other DPP-4 inhibitors like vildagliptin, saxagliptin, linagliptin, and newer agents.
Key Considerations for R&D and Investment Decisions
For pharmaceutical companies and investors, KR20100130989 and its surrounding landscape necessitate several strategic considerations:
- Patent Expiry Timeline: The approaching expiry of KR20100130989 (around 2029) provides a window for generic market entry or the development of next-generation therapies that differentiate from the patented combination.
- Freedom-to-Operate (FTO) Analysis: A comprehensive FTO analysis is crucial before developing or launching any metformin-DPP-4 inhibitor combination product. This involves scrutinizing existing patents, including KR20100130989 and others, to identify potential infringement risks.
- Portfolio Assessment: Companies should assess their existing patent portfolio related to diabetes treatments. This includes evaluating opportunities for filing new patents on improved formulations, novel combinations, or synergistic therapies that could offer extended market exclusivity.
- Licensing and Acquisition Opportunities: The expiration of patents can create opportunities for licensing existing technologies or acquiring companies with innovative diabetes treatments.
- Therapeutic Differentiation: Given the crowded market for metformin-DPP-4 inhibitor combinations, any new product must offer clear therapeutic advantages, such as improved efficacy, safety profile, patient convenience, or cost-effectiveness, to gain market traction.
- Regulatory Pathway: Understanding the regulatory requirements in South Korea for the approval of fixed-dose combination drugs is essential. This includes demonstrating bioequivalence for generic products and substantial evidence of efficacy and safety for novel combinations.
Key Takeaways
- Patent KR20100130989, held by Daewoong Pharmaceutical Co., Ltd., protects a pharmaceutical composition combining metformin with a dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes treatment.
- The patent's scope, particularly Claim 1, is broad, covering any DPP-4 inhibitor, with sitagliptin specified in Claim 2.
- The patent is scheduled to expire around 2029, marking a critical date for potential generic competition and market entry strategies.
- The patent landscape for metformin-DPP-4 inhibitor combinations is competitive, with numerous active patents from global and domestic pharmaceutical companies.
- Companies are advised to conduct thorough freedom-to-operate analyses to navigate potential infringement risks and to focus on therapeutic differentiation for new product development.
FAQs
1. What is the current patent status of KR20100130989?
Patent KR20100130989 is an active patent in South Korea, filed on December 15, 2009, and granted on December 17, 2010. It is expected to expire around December 15, 2029.
2. Does KR20100130989 cover all DPP-4 inhibitors when combined with metformin?
Yes, Claim 1 of KR20100130989 broadly covers a pharmaceutical composition comprising metformin and "a dipeptidyl peptidase-4 (DPP-4) inhibitor." While sitagliptin is specified in a subsequent claim, the foundational claim is not limited to a specific DPP-4 inhibitor.
3. What are the implications of this patent's upcoming expiration?
The expiration of KR20100130989 will remove patent protection for the specific combination it covers, potentially allowing for the introduction of generic versions of such a pharmaceutical composition in the South Korean market, assuming no other relevant patents are in force.
4. Who is the assignee of patent KR20100130989?
The assignee of patent KR20100130989 is Daewoong Pharmaceutical Co., Ltd.
5. What specific therapeutic area does KR20100130989 address?
KR20100130989 addresses the therapeutic area of type 2 diabetes mellitus.
Citations
[1] Daewoong Pharmaceutical Co., Ltd. (2010). Pharmaceutical composition containing metformin and DPP-4 inhibitor. (KR20100130989). Korean Intellectual Property Office.
